证券记录 · 已归档季度
NRIX
Nurix Therapeutics, Inc. · Healthcare · Biotechnology
18被追踪持有人
+1Δ持有人
36.35M持有股份
$335.90M报告持仓市值
+1新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +5.9% ·
股份流向 -13.0% ·
净新建仓位 +5.6%
· 公式
持有人分散化：持有人数增多，合计持仓比例缩小。
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | +2 | 57.55M | $1.40B | +9 | −7 |
| Q1 2026 | 81 | +9 | 58.06M | $899.96M | +14 | −5 |
| Q4 2025 | 72 | -4 | 55.79M | $1.06B | n/a | −4 |
| Q3 2025 | 18 | +1 | 36.35M | $335.90M | +1 | n/a |
| Q2 2025 | 14 | -2 | 38.82M | $442.11M | n/a | −2 |
| Q1 2025 | 13 | 0 | 15.31M | $181.88M | +1 | −1 |
| Q4 2024 | 13 | -1 | 15.53M | $292.61M | +1 | −2 |
| Q3 2024 | 13 | -1 | 13.04M | $292.98M | +1 | −2 |
| Q2 2024 | 14 | n/a | 12.64M | $263.85M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 8.89M | -14.9% | $82.12M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (被动) | 6.76M | -0.7% | $62.49M | 0.0% | ▼ Trim | 2 | SEC ↗ ×14 |
| 3 | The Vanguard Group ✦ (被动) | 4.49M | +0.5% | $41.48M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 4 | Point72 Asset Management ✦ | 2.87M | -22.5% | $26.53M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (被动) | 2.86M | +13.0% | $26.45M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Morgan Stanley ✦ | 2.26M | n/a | $20.89M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 7 | Geode Capital Management ✦ (被动) | 1.88M | 0.0% | $17.40M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Millennium Management ✦ | 1.52M | +64.3% | $14.08M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 9 | ARK Investment Management ✦ | 1.51M | -4.1% | $13.96M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 1.10M | -63.8% | $10.16M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 11 | Goldman Sachs Group ✦ | 622.30K | n/a | $5.75M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Citadel Advisors ✦ | 565.30K | -64.4% | $5.22M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 13 | Wellington Management ✦ | 255.79K | -82.5% | $2.36M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 14 | Marshall Wace ✦ | 246.79K | 新增 | $2.28M | 0.0% | New | 1 | SEC ↗ ×2 |
| 15 | Renaissance Technologies ✦ | 184.80K | +743.8% | $1.71M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | PRIMECAP Management ✦ | 170.00K | -19.1% | $1.57M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | JPMorgan Chase ✦ | 95.07K | n/a | $878,410 | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 18 | Two Sigma Investments ✦ | 62.88K | -60.4% | $580,965 | 0.0% | ▼ Trim | 6 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $2.28M | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 194 持有人, 116.98M 股份, $1.75B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 15
Hansen Gwenn
Officer · 1.45K 股 · $36,300
Oct 14
GREGORY JULIA P
Director · 22.58K 股 · $528,528
Sep 01
Hansen Gwenn
Officer · 1.45K 股 · $36,982
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Sep 23
SC 13G: PERCEPTIVE ADVISORS LLC
Aug 14
SC 13G/A: Redmile Group, LLC
Aug 14
SC 13G/A: Vestal Point Capital, LP
Aug 14
SC 13G: Rubric Capital Management LP
Aug 14
SC 13G: PRICE T ROWE ASSOCIATES INC /MD/
Aug 14
SC 13G/A: Deep Track Capital, LP
Jul 31
SC 13G: VANGUARD CAPITAL MANAGEMENT LLC
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据